This guide presents the clinical evidence on GLP-1 medications in adolescents without advocacy for or against use. The evidence for benefit in adolescent obesity is real. So are the unanswered long-term questions about development. Both deserve honest presentation. The decision to treat is a clinical one, made between a family and a qualified healthcare provider — not a Reddit one, and not a decision made based on a guide like this one in isolation.
GLP-1 medications for weight management require a valid prescription. Nothing in this guide should be read as recommending or discouraging any specific treatment decision for any individual adolescent.
What Is Approved — The Current Regulatory Landscape for GLP-1s in Adolescents
Strong — FDA approval based on controlled clinical trials with clear regulatory basisThe regulatory question — what is FDA-approved — is the easiest part of this topic to answer. What is appropriate for a specific adolescent is the harder clinical question, addressed in later sections. Understanding the regulatory basis helps frame the evidence standards that justified approval and the gaps the approval does not address.
FDA-Approved GLP-1 Medications for Adolescents (as of June 2026)
Approved age: 12 and older · Indication: Obesity (BMI ≥95th percentile for age and sex) · Dose: 2.4mg weekly injection
Wegovy received FDA approval for adolescents in December 2022, based primarily on the STEP TEENS trial. The approval covers adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex — the clinical definition of obesity in pediatric populations. The approval requires use alongside diet and physical activity modification. Semaglutide requires a valid prescription from a licensed healthcare provider.
Approved age: 12 and older · Indication: Obesity (BMI ≥95th percentile, body weight >60kg) · Daily subcutaneous injection
Liraglutide (Saxenda) was approved for adolescent obesity in 2020, making it the first GLP-1 receptor agonist to receive this indication. The approval was based on a phase 3 randomized trial showing meaningful weight reduction versus placebo. Liraglutide has a shorter history of post-market use in adolescents than in adults, and requires daily rather than weekly injection.
Adult approval: 2023 · Pediatric trials: Ongoing as of early 2026 · Prescribers should verify current FDA label before prescribing off-label
Tirzepatide (Zepbound) received FDA approval for adults with obesity in 2023. As of the time this guide was written in June 2026, pediatric clinical trials for tirzepatide in adolescents were either ongoing or had recently completed. Families and prescribers should verify the current FDA approval status for tirzepatide in adolescents before considering its use, and should consult with a pediatric obesity medicine specialist regarding any use in minors. Any use prior to explicit pediatric approval would constitute off-label use, which carries different risk and documentation considerations.
What Approval Does and Does Not Mean
FDA approval for a pediatric indication means that the drug was studied in the relevant age group, demonstrated a statistically significant and clinically meaningful primary endpoint (typically weight reduction), and the benefit-risk assessment in the studied population supported approval. It does not mean that all long-term questions have been answered. Pediatric approvals can be granted on relatively short trial durations — the STEP TEENS trial was 68 weeks — because withholding treatment for the years required to gather long-term data would itself be ethically problematic when meaningful short-term benefit is documented.
The sections that follow address what the trial data showed, and equally important, what it did not assess.
Compounded semaglutide and tirzepatide — widely available in the adult market from telehealth providers during periods of branded drug shortage — are not appropriate for use in adolescents and minors. Compounded preparations lack pediatric dosing validation, FDA regulatory oversight, and manufacturing standards applicable to branded drugs. The clinical trials that support GLP-1 use in adolescents used FDA-approved formulations at validated, age-appropriate doses. Compounded products cannot be assumed to be bioequivalent, and the risk calculus for adults choosing compounded drugs for cost or access reasons is different from the considerations that apply to treating minors. Any GLP-1 use in adolescents should involve only FDA-approved products under the care of a qualified prescriber with pediatric expertise.
The Adolescent Trial Evidence — What the Clinical Studies Actually Show
Moderate — Randomized controlled trials exist; follow-up duration limited; key developmental endpoints not assessedThe clinical trial evidence for GLP-1 medications in adolescents is real and meaningful within its scope. Understanding its scope precisely is as important as knowing its findings, because the honest picture includes both the demonstrated benefits and the limitations of the studies that produced those findings.
201 adolescents · Ages 12–17 · BMI ≥95th percentile · 68 weeks · Semaglutide 2.4mg vs. placebo, both with lifestyle intervention
Primary finding: participants receiving semaglutide achieved a mean body weight reduction of 16.1% from baseline, compared to a mean increase of 0.6% in the placebo group. This is a large, clinically meaningful difference that substantially exceeds what lifestyle intervention alone achieves in adolescent obesity trials. At week 68, a substantially higher proportion of semaglutide participants had achieved 5%, 10%, and 15% or greater weight reductions compared to placebo.
Cardiometabolic Outcomes in STEP TEENS
Beyond weight reduction, STEP TEENS documented meaningful improvements in cardiometabolic markers in the semaglutide group. These included reductions in blood pressure, improvements in fasting insulin levels and insulin sensitivity markers, and improvements in lipid parameters including triglycerides and HDL cholesterol. These findings are clinically relevant because the comorbidities of adolescent obesity — insulin resistance, hypertension, dyslipidemia — are the mechanisms through which obesity causes long-term harm. Meaningful improvements in these markers in a 68-week trial represent real clinical benefit, not only a scale number.
The magnitude of cardiometabolic improvement tracked roughly with the degree of weight reduction, which is consistent with what adult trials show. Adolescents with the greatest weight reduction showed the greatest cardiometabolic improvement. This pattern is expected and supports the biological plausibility of the findings.
GI Side Effects and Discontinuation in Adolescents
The side effect profile of semaglutide in STEP TEENS was similar in character to the adult experience: predominantly gastrointestinal, including nausea, vomiting, diarrhea, and constipation, most prominent during dose escalation and generally diminishing after reaching a maintenance dose. However, discontinuation rates for adverse events were somewhat higher in the adolescent trial than in comparable adult trials. This may reflect developmental differences in GI sensitivity, differences in the support infrastructure available to adolescents versus adults managing side effects, or differences in the threshold at which adolescents or their families choose to discontinue. The higher discontinuation rate is worth noting when counseling families about what to expect.
What the STEP TEENS Trial Did Not Assess
Honest characterization of the STEP TEENS evidence requires acknowledging what the trial was not designed to measure. The trial did not include bone density assessment as a primary or secondary endpoint. It did not include long-term growth assessments beyond the trial period. It did not include systematic psychiatric outcome assessments, including eating disorder screening. It did not assess effects on puberty progression or timing. And at 68 weeks, it does not tell us what happens to treated adolescents over 3, 5, or 10 years — time horizons that matter for developmental questions. The trial answered whether semaglutide reduces weight in adolescents with obesity over 68 weeks. It answered that question well. It was not designed to answer the developmental questions addressed in Section 3.
Liraglutide (Saxenda) has a separate adolescent evidence base from its 2020 approval. The liraglutide adolescent trial showed weight reduction compared to placebo, though the magnitude was somewhat smaller than what semaglutide achieved in STEP TEENS. Liraglutide requires daily injection versus semaglutide's weekly injection, which affects adherence in adolescent populations. The side effect profiles are broadly similar. Liraglutide has a longer post-market history in adults but not substantially longer in the adolescent indication, given the timing of both approvals.
Unanswered Long-Term Questions — What We Do Not Yet Know About Adolescent Development
Limited — No long-term controlled data on bone density, growth, puberty timing, or psychiatric outcomes in GLP-1-treated adolescentsFDA approval is not a statement that all long-term questions have been answered. In pediatric drug approvals, it is a statement that the short-term benefit-risk balance supports approval, with the expectation that post-market surveillance and further studies will address the longer-term questions. For GLP-1s in adolescents, several of those questions remain genuinely open. Presenting them honestly is not fearmongering — it is the accurate characterization of where the science stands.
Bone Density — The Critical Developmental Window
Adolescence is the primary period during which humans build peak bone mass. Approximately 90% of peak bone mineral density is achieved by the mid-twenties, and the rate of bone mass accumulation is highest during puberty. Peak bone mass is a major determinant of fracture risk across the entire lifespan — the higher the peak, the more bone loss from aging and other causes can occur before fracture risk becomes clinically significant.
The concern with GLP-1 medications during this period is not that they have been shown to reduce bone density in adolescents — they have not been studied for this outcome in controlled trials. The concern is that any intervention that reduces caloric intake, causes significant weight loss, or alters hormonal milieu during this critical window has the potential to affect bone accrual, and the trials that supported FDA approval did not assess this outcome.
In adults, some data from bariatric surgery and pharmacological weight loss interventions suggests that rapid weight loss can be associated with reductions in bone mineral density, particularly when protein intake and resistance exercise are not maintained. Whether this applies to GLP-1-driven weight loss in adolescents — and whether it would be clinically significant — is not yet known from controlled data. This is not a reason to refuse treatment for severe adolescent obesity, which has its own documented effects on bone health and comorbidities. It is a reason to monitor bone density and to ensure that treated adolescents receive adequate calcium, vitamin D, and weight-bearing activity — and to track this over time.
Limited — No controlled bone density data in GLP-1-treated adolescents; adult post-bariatric data suggests monitoring is warrantedLinear Growth — Short Trials, Long Growing Periods
The STEP TEENS trial did not show significant impairment in linear growth (height) during its 68-week period. This is reassuring for the near-term, and it is the data we have. The limitation is that 68 weeks is a relatively short window relative to the period during which adolescents grow. Adolescent growth continues through the mid-to-late teenage years and, in some individuals, into the early twenties. A trial that ends at 68 weeks does not tell us what happens to growth trajectories over the full remaining growth period.
Significant caloric restriction or changes in growth hormone and IGF-1 levels associated with weight changes could theoretically affect growth trajectory, even if no effect is visible in a short trial. The direction and magnitude of any such effect in adolescents treated with GLP-1s has not been established from long-term data. Again, this is not a contraindication to treatment in appropriate patients — it is a gap in the evidence that warrants monitoring height velocity in treated adolescents and understanding that the long-term picture has not yet been fully characterized.
Limited — No significant growth impairment in trial period; no long-term growth data availablePuberty Timing and Hormonal Effects
Weight and adiposity are well-established modulators of puberty timing. Obesity in adolescents is associated with earlier puberty onset in girls, and the relationship in boys is more complex. GLP-1-driven weight reduction in adolescents therefore has the potential to alter puberty timing or progression — in either direction, depending on the direction of the weight change, the patient's baseline, and the stage of puberty at treatment initiation.
This is not inherently adverse. Delaying precocious puberty, normalizing puberty timing, or reversing obesity-related pubertal disruption could be beneficial. But the clinical trial data does not include systematic assessment of puberty staging, hormone levels, or puberty timing outcomes in treated adolescents. The implications of GLP-1-driven weight changes for puberty progression during active treatment — and for the hormonal environment that governs long-term reproductive health — have not been characterized in controlled long-term studies. This is an open question, not a documented harm.
Emerging — Biological plausibility for effects on puberty timing; no controlled data in GLP-1-treated adolescentsEating Disorder Risk — A Genuine Open Question
Pharmacological appetite suppression during adolescence raises specific psychological considerations that deserve careful treatment. Adolescence is the developmental period during which eating disorders most commonly emerge. The prevalence of disordered eating and clinical eating disorders is substantially higher in adolescents with obesity than in the general population. Introducing a medication that suppresses appetite and dramatically alters the subjective experience of hunger and fullness during this developmental period has not been studied in long-term psychiatric outcome trials.
This uncertainty cuts in both directions. On one hand, there is a theoretical concern that pharmacological appetite suppression could interact with eating disorder vulnerability in ways that are harmful for some adolescents. On the other hand, some clinicians and researchers have proposed that reducing the distress associated with food cravings and weight gain could potentially reduce eating disorder risk for some adolescents for whom the psychological burden of obesity is itself a risk factor. The long-term psychiatric outcome data in GLP-1-treated adolescents does not yet exist to resolve this question in either direction.
This uncertainty is a strong argument for incorporating systematic eating disorder screening and ongoing mental health monitoring into any GLP-1 treatment protocol for adolescents — not as a barrier to treatment, but as part of responsible care. It is also a reason why treatment in adolescents should be managed by or in consultation with specialists who have training in pediatric eating disorders as well as obesity medicine.
Limited — No long-term psychiatric outcome data in GLP-1-treated adolescents; theoretical risk and benefit signals present; monitoring is essentialIt is critical to read the open questions in this section in their proper context. Severe adolescent obesity has documented, serious, well-characterized consequences: type 2 diabetes, hypertension, dyslipidemia, PCOS, obstructive sleep apnea, non-alcoholic fatty liver disease, orthopedic complications, depression, and substantially elevated cardiovascular risk across the lifespan. The known harms of untreated severe obesity are real, documented, and serious. The open questions about GLP-1 use during development are genuine uncertainties, not documented harms. For a patient with severe obesity and significant comorbidities, the known consequences of no treatment must be weighed against the theoretical and unknown risks of treatment. That tradeoff is a clinical judgment — not one that can be made by reading a list of unknowns in isolation.
The Obesity Treatment Context — Understanding the Clinical Tradeoff
Strong — Consequences of severe adolescent obesity are well-documented; AAP 2023 guidelines support pharmacotherapy alongside lifestyle interventionDiscussions of GLP-1 use in adolescents that focus only on the trial data without addressing the consequences of untreated severe pediatric obesity present an incomplete picture. The tradeoff is not between GLP-1 medications and a risk-free baseline of doing nothing. The tradeoff is between the known consequences of untreated severe obesity and the demonstrated benefits and unknown long-term questions associated with treatment.
The Well-Documented Consequences of Severe Adolescent Obesity
Severe obesity in adolescents is not a cosmetic concern or a lifestyle choice that resolves with time. The clinical literature documents serious, progressive comorbidities that begin in adolescence and track into adulthood:
- Type 2 diabetes: Adolescent obesity is the primary driver of the dramatic increase in type 2 diabetes in pediatric populations. Adolescent-onset type 2 diabetes is more aggressive and more difficult to manage than adult-onset disease, with faster progression to complications.
- Hypertension and cardiovascular risk: Obesity-related hypertension in adolescents is common and is associated with elevated lifetime cardiovascular risk. Early atherosclerotic changes have been documented in adolescents with obesity, particularly those with metabolic syndrome features.
- Polycystic ovary syndrome (PCOS): Obesity is a major driver and amplifier of PCOS, which is the most common endocrine disorder in women of reproductive age. Adolescent obesity substantially increases the risk and severity of PCOS.
- Obstructive sleep apnea: Prevalence is substantially elevated in adolescents with obesity and is associated with daytime fatigue, neurocognitive effects, and cardiovascular consequences.
- Non-alcoholic fatty liver disease (NAFLD): Increasingly prevalent in adolescents with obesity; can progress to steatohepatitis and, over decades, to cirrhosis.
- Depression and psychological burden: The psychological consequences of adolescent obesity include elevated rates of depression, anxiety, low self-esteem, and social isolation. These are documented clinical outcomes, not incidental concerns.
- Orthopedic complications: Including Blount's disease (tibia vara) and slipped capital femoral epiphysis, which are disproportionately prevalent in adolescents with severe obesity.
Critically, severe adolescent obesity tracks strongly into adult obesity. The majority of severely obese adolescents who do not receive effective intervention remain obese as adults, carrying all of the above comorbidities — plus the additional decades of cardiovascular, metabolic, and oncological risk that adult obesity confers — into their adult lives. The clinical trajectory of untreated severe adolescent obesity is not benign.
Lifestyle Intervention Alone — What the Evidence Shows
The instinct to attempt lifestyle intervention before medication is appropriate, and the American Academy of Pediatrics guidelines support it as the foundation of treatment. However, the success rates of lifestyle intervention alone in severe pediatric obesity are modest. The most intensive lifestyle programs — those involving frequent contact, family participation, dietary modification, and structured physical activity — achieve mean weight reductions on the order of 3 to 5 percent of body weight over 12 months in adolescents with obesity. For an adolescent at the 99th percentile for BMI, a 3 to 5 percent weight reduction leaves them well within the obesity range with persistent comorbidities. The gap between what lifestyle intervention alone typically achieves in severe pediatric obesity and what would be clinically meaningful is substantial.
This is the clinical context in which pharmacotherapy has entered the picture. The AAP 2023 Clinical Practice Guideline on Pediatric Obesity explicitly recommends offering pharmacotherapy alongside intensive health behavior and lifestyle treatment for adolescents 12 and older with obesity. The guideline represents a significant shift from prior guidance that took a more conservative approach to medication, and it reflects the accumulated evidence that lifestyle intervention alone has limitations in severe pediatric obesity and that the known consequences of leaving severe obesity untreated are serious.
The American Academy of Pediatrics 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity recommends offering weight loss pharmacotherapy as a component of comprehensive obesity treatment for adolescents 12 years and older when criteria are met, alongside intensive health behavior and lifestyle treatment. The guideline also recommends referral to a pediatric obesity medicine specialist when available. The guideline explicitly moves away from a “watch and wait” approach in adolescents with obesity and comorbidities.
The Clinical Tradeoff — Framed Honestly
The honest framing of the treatment decision for an adolescent with severe obesity is not “GLP-1 medications have some unknowns, therefore we should wait.” It is: what are the known consequences of continued untreated severe obesity for this specific patient, and how do they compare to the demonstrated benefits and open long-term questions associated with GLP-1 treatment? For a 14-year-old with a BMI at the 99th percentile, type 2 diabetes, hypertension, and sleep apnea, the consequences of continued untreated disease are not abstract. They are documented, progressive, and serious. For that patient, the calculus may strongly favor treatment despite the open developmental questions. For a different patient with a borderline BMI and no comorbidities, the calculus is different. That is why it is a clinical decision, not a policy decision.
The tradeoff is not between GLP-1 medications and a risk-free baseline. It is between documented, serious consequences of untreated severe adolescent obesity and demonstrated short-term benefits alongside unanswered long-term developmental questions. That calculation requires a clinician who knows the patient — not a generalized position for or against medication.
Questions Families Should Ask Before an Adolescent Starts GLP-1 Therapy
Moderate — Questions grounded in clinical evidence gaps and best-practice monitoring standardsFor families navigating a GLP-1 recommendation for an adolescent, the clinical landscape can feel overwhelming. These are not simple decisions, and the information environment around GLP-1s in minors includes strong advocacy in both directions that does not always reflect the nuanced evidence. The following questions are designed to help families have an informed conversation with a prescribing physician, not to create obstacles to appropriate treatment.
- What is the documented diagnostic basis? What is the adolescent's current BMI percentile, and how does it meet the criteria for the specific medication being prescribed? Has a full medical evaluation been completed including screening for comorbidities?
- What lifestyle interventions have been tried, and for how long? The AAP guidelines recommend pharmacotherapy alongside, not instead of, intensive lifestyle intervention. What dietary, behavioral, and physical activity interventions are part of the treatment plan, and how will they be structured and supported?
- Who will monitor bone density and growth? Given the open questions about bone accrual during GLP-1 treatment in adolescents, what is the monitoring plan? Will DEXA scans or bone density assessments be performed? How will height velocity be tracked? What triggers a referral to an endocrinologist or specialist?
- How will psychological and eating disorder risk be monitored? What screening tools will be used? How frequently? If the adolescent has any history of disordered eating or eating disorder diagnosis, how does that factor into the treatment plan? Is a mental health professional part of the care team?
- What is the long-term treatment plan? GLP-1 medications require ongoing use to maintain weight loss. What is the expected duration of treatment? What are the criteria for continuing treatment into adulthood? What is the plan for transition to adult providers? Has the family been counseled that weight typically returns after discontinuation?
- What are the criteria for pausing or stopping the medication? What clinical or psychological findings would prompt a pause or discontinuation? Who makes that call, and how is it communicated to the family?
- Is this prescriber a pediatric obesity medicine specialist, or should a specialist consult be part of the evaluation? Pediatric obesity medicine is a recognized subspecialty. For adolescents with complex comorbidities, significant psychiatric history, or other complicating factors, a specialist referral is appropriate and families can advocate for one.
These questions are not designed to be adversarial. Most physicians who prescribe GLP-1s for adolescents are asking themselves all of them. They are designed to help families participate in the clinical conversation as informed partners, which generally produces better care and better adherence outcomes.
Families should also be aware that if their primary care physician declines to prescribe GLP-1s for an adolescent with obesity, that may reflect appropriate caution and a preference for specialist evaluation — or it may warrant a referral to a pediatric obesity medicine specialist who has more experience making these decisions. The appropriate response to a declined prescription depends on the specifics of the clinical picture and the prescriber's reasoning. In some cases, a second opinion from a specialist is appropriate.
The American Board of Obesity Medicine (ABOM) and the Obesity Medicine Association maintain resources for finding board-certified obesity medicine specialists. For adolescents, physicians with board certification in pediatrics plus obesity medicine training are the highest-credential combination for this type of care. Academic medical centers with pediatric obesity programs often offer multidisciplinary teams that include dietitians, behavioral health specialists, and endocrinologists alongside the prescribing physician.
The Misinformation Problem — What to Ignore and What to Investigate
Moderate — This section reflects documented patterns of GLP-1 misinformation; sources should be evaluated criticallyThe information environment around GLP-1 medications for adolescents is particularly noisy. Parents doing their own research encounter a mix of legitimate clinical concerns, advocacy from people with strong views in both directions, anecdotal reports that may not generalize, and content that is simply wrong. Navigating that environment requires some ability to identify which sources and claims are worth taking seriously.
Reddit and Social Media — Wrong Population, Wrong Context
Reddit's GLP-1 communities — particularly r/Ozempic, r/WegovyWeightLoss, and similar forums — contain useful peer experience about adult GLP-1 use. They are not a reliable source of information about adolescent GLP-1 use. The overwhelming majority of people sharing experiences in those communities are adults who were prescribed these medications for adult indications, at adult doses, with adult physiology and adult-onset obesity. Their experiences with side effects, dosing, weight loss trajectories, and psychological effects do not directly transfer to a 13-year-old with pubertal-stage development and a different clinical context.
Parents who read adult GLP-1 experiences and apply them to pediatric decision-making are working with the wrong dataset. The questions relevant to adolescent treatment — bone density, growth, puberty, eating disorder risk — are rarely discussed in adult GLP-1 communities because they are not relevant to adult users. The absence of discussion of those concerns in adult forums is not evidence that those concerns are unfounded for adolescents.
Compounded GLP-1 for Minors — Specifically Not Appropriate
The adult market for compounded semaglutide and tirzepatide emerged during periods of branded drug shortage and has persisted as a lower-cost alternative for adults who find branded drugs unaffordable. Some compounding pharmacies market directly to consumers, including families, and the regulatory environment around compounding pharmacies does not prevent them from dispensing to minors if a prescribing physician orders it.
Compounded GLP-1 preparations for adolescents carry risks that go beyond those applicable to adult users. There is no pediatric dosing validation for compounded formulations. Compounding pharmacies are not required to conduct and have not conducted pediatric pharmacokinetic studies. The dose escalation protocols used in adult compounding contexts were not designed for adolescents. The impurity and potency standards applicable to branded FDA-approved products do not apply in the same way to compounded preparations. For an adult making an informed risk-benefit choice about a compounded drug for themselves, these are relevant considerations. For a parent making that choice about a minor, the risk threshold is different. GLP-1 therapy for adolescents should involve FDA-approved formulations only.
“My Doctor Refused” — Caution vs. Gatekeeping
A recurring theme in online discussions is frustration from parents whose physicians declined to prescribe GLP-1 medications for their adolescent child. In some cases, that refusal reflects appropriate clinical caution — the physician has evaluated the patient and concluded that the evidence does not support medication at this time, that the comorbidity burden does not yet justify pharmacotherapy, or that the patient's psychiatric history warrants a mental health consultation before initiating appetite suppression. Those are legitimate clinical judgments.
In other cases, the refusal reflects unfamiliarity with the current evidence base or the 2023 AAP guidelines, discomfort prescribing GLP-1s in pediatric populations, or a general preference for lifestyle-only approaches that is not aligned with current evidence for severe pediatric obesity. A physician who has not read the AAP 2023 guidelines or the STEP TEENS data is not in the best position to counsel a family on this question.
The appropriate response to a declined prescription is not to find a telehealth service willing to prescribe without adequate evaluation, and it is not to seek compounded alternatives. It is to understand why the physician declined, to ask whether a specialist referral to a pediatric obesity medicine program is appropriate, and to ensure that the evaluation was thorough. A second opinion from a specialist with pediatric obesity expertise is always appropriate when a family has concerns about whether a primary care decision was fully informed.
The online information environment includes both parents who strongly advocate for GLP-1 use in adolescents and parents who strongly advocate against it. Both camps contain people with real experience and genuine concern for children's health. Neither camp is a substitute for an individualized clinical evaluation. The family whose teenager had a transformative experience with semaglutide and the family whose teenager had a difficult experience with GI side effects or mood changes are both sharing real data points. Neither of those n=1 stories tells you what the right decision is for a different child in a different clinical situation. The clinical evidence and the specialist evaluation do that.
Frequently Asked Questions
Is semaglutide (Wegovy) approved for teenagers?
Yes. Wegovy (semaglutide 2.4mg) received FDA approval in December 2022 for adolescents aged 12 and older with obesity, defined as a BMI at or above the 95th percentile for age and sex. This approval was based primarily on the STEP TEENS clinical trial, which demonstrated a mean body weight reduction of 16.1% over 68 weeks compared to 0.6% in the placebo group. Liraglutide (Saxenda) has also been FDA-approved for adolescents 12 and older since 2020. These medications require a valid prescription from a licensed healthcare provider — typically a pediatrician, family physician, or pediatric obesity medicine specialist. Compounded versions are not approved for any age group and are not appropriate for use in minors.
What did the STEP TEENS trial show about semaglutide in adolescents?
The STEP TEENS trial enrolled 201 adolescents aged 12 to 17 with obesity and treated them with semaglutide 2.4mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide group achieved a mean body weight reduction of approximately 16.1% compared to 0.6% in the placebo group — a clinically and statistically meaningful difference. Participants also showed improvements in cardiometabolic markers including blood pressure, fasting insulin, and lipid levels. GI side effects were similar in character to those seen in adults, though discontinuation rates were slightly higher in adolescents. Importantly, the trial did not include bone density assessment as an endpoint, and follow-up was under two years — too short to assess long-term developmental outcomes including bone accrual, growth trajectory, puberty timing, or psychiatric outcomes.
What are the unanswered long-term questions about GLP-1 use in adolescents?
The major open questions include: (1) Bone density — adolescence is the primary period for building peak bone mass, and caloric restriction or significant weight loss may impair this accumulation; no long-term bone density data exists for GLP-1-treated adolescents; (2) Linear growth — trials showed no significant impairment during the study period, but trial durations were short relative to the full growth period; (3) Puberty timing — weight changes can affect hormone levels and puberty progression, and long-term implications are not yet characterized; (4) Eating disorder risk — pharmacological appetite suppression during adolescent development has not been studied in long-term psychiatric outcome trials. None of these unknowns are arguments against treatment in adolescents with severe obesity. They are arguments for specialist involvement, systematic monitoring, and ensuring that the care plan includes provisions for tracking these outcomes over time.
Should a teenager with obesity take GLP-1 medications?
This is a clinical decision, not one that a research guide can answer. The American Academy of Pediatrics 2023 guidelines recommend offering pharmacotherapy — including GLP-1 medications — alongside intensive health behavior and lifestyle intervention for adolescents with obesity. The guidelines reflect a recognition that lifestyle interventions alone have modest success rates in severe pediatric obesity, and that the known consequences of untreated severe obesity (type 2 diabetes, hypertension, cardiovascular risk, PCOS, depression, joint problems) are serious and well-documented. Whether a specific adolescent should begin GLP-1 therapy requires a full medical evaluation by a qualified healthcare provider — ideally a pediatric obesity medicine specialist — who can assess the individual's medical history, comorbidities, mental health history, and prior treatment attempts. This guide provides background information; it does not substitute for that clinical evaluation.
Is compounded semaglutide or tirzepatide safe for adolescents?
No. Compounded GLP-1 preparations are not appropriate for use in adolescents and minors. Compounded versions lack pediatric dosing validation, are not FDA-approved, and carry no regulatory oversight ensuring purity, potency, or safety at doses appropriate for adolescent use. The clinical trials that support GLP-1 use in adolescents were conducted with FDA-approved formulations at validated, age-appropriate doses. Compounded products cannot be assumed to be bioequivalent. Adults making their own risk-benefit decisions about compounded GLP-1s face a different calculus than parents choosing treatments for minors. For adolescents, GLP-1 therapy should involve only FDA-approved products (Wegovy for semaglutide, Saxenda for liraglutide) prescribed by a qualified physician with appropriate pediatric expertise.
What questions should families ask before an adolescent starts GLP-1 therapy?
Families should ask: (1) What is the documented basis for the obesity diagnosis and what BMI criteria does it meet? (2) What lifestyle and behavioral interventions have been tried, for how long, and what were the results? (3) What monitoring will be in place for bone density, linear growth, and psychological outcomes, including eating disorder screening? (4) What is the long-term treatment plan — GLP-1 medications require ongoing use to maintain weight loss, and the plan for eventual discontinuation or continuation into adulthood should be discussed upfront? (5) How will eating disorder risk be monitored and what are the criteria that would prompt a pause in treatment? (6) Is this prescriber a pediatric obesity medicine specialist or should a specialist referral be part of the evaluation? These questions are not obstacles to treatment — they are the framework for informed, appropriate, well-monitored treatment.